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In the period 1980-1985, we treated 1641 patients for tuberculosis of whom two were known to be intravenous drug users 
(IVDU) and none had HIV infection. Of the next 1000 patients treated for tuberculosis (January 1986-December 1989), six were 
HIV-negative intravenous drug users (IVDU), 18 patients were HIV-positive (12 IVDU; six homosexual/bisexual). Statistical 
analysis (X2:) showed a numerically small but statistically significant (P<0.00001, d.f. = l, X2 = 20-38) increase in intravenous 
drug users with a diagnosis of tuberculosis. The HIV-positive patients who completed treatment responded well to anti-
tuberculous drugs. 
 The importance of tuberculosis in the context of HIV infection is that it is preventable, treatable and is the only Bacterial 
infection to which HIV subjects are prone which can be readily transmitted to a non-HIV infected subject. 
 
become rapidly progressive to active disease following recent 
infection. 
Introduction 
 Tuberculosis (TB) is well recognized as one of the most 
common bacterial infections in patients infected with Human 
Immunodeficiency Virus (HIV). While the lifetime risk of 
active disease following primary infection is said to be the 
order of 10% in an immunocompetent subject, the risk of 
active disease is believed to be up to 30% in a HIV-positive 
subject (1). It is possible that tuberculosis, even if successfully 
treated, may accelerate the progression of HIV infection to 
AIDS (2,3). Tuberculosis in otherwise normal individuals has 
a number of immunosuppressive effects including increased 
production of acute phase reactants, some of which may 
suppress certain lymphocytic functions (4), and even induction 
of CD4 lymphopenia (5). Immunological mediators produced 
during infection may augment the replication of HIV virus in 
lymphocytes and monocytes. 
 We have previously noted the occurrence of tuberculosis 
in patients infected with HIV in the Republic of Ireland (7). 
We have also reported the incidence of disease due to 
mycobacteria other than tuberculosis (MOTT) as eight per 
1000 positive myco-bacterial cultures (8). In a retrospective 
study covering the period January 1980-December 1985, only 
two out of 1641 patients treated for tuberculosis were known 
intravenous drug users (IVDU). Their HIV status is unknown. 
 Tuberculosis in HIV-positive subjects may be difficult to 
diagnose as the typical radiological appearances may not 
occur. Indeed many of the features are more consistent with 
primary infection (9-11). The tuberculosis is not confined to 
the apices, cavitation may be absent, there may be widespread 
pulmonary involvement and frequently there is hilar or 
medias-tinal gland involvement. There is also frequently 
extrapulmonary disease (9,10,12).  A steady increase in the incidence of tuberculosis in the 
United States of America has been attributed to the AIDS 
epidemic (1). The question is whether tuberculosis among 
HIV-positive subjects is due to recent infection and early 
progression of disease or due to reactivation of previous latent 
infection. In their study in New York, Selwyn et al. (6) 
suggested that in HIV infected persons, tuberculosis most 
often resulted from reactivation of latent disease. It is possible, 
however, that in HIV-positive subjects, because of declining 
immunocompetence, that tuberculosis may 
 We treat all patients with tuberculosis, including patients 
who are HIV-positive with standard anti-tuberculous regimens 
(13,14). 
 The aims of the study were to determine the number of 
cases of mycobacterial disease, both TB and MOTT, in HIV-
positive patients and in intravenous drug users (IVDU) treated 
in the period January 1986-December 1989 inclusive in the 
Department of Genito-Urinary Medicine, St. James’ Hospital 
and Peamount Chest Hospital. Dublin. We considered the 
organisms involved, clinical presentation, radiological extent 
of disease, response to therapy and relapse rate. Received 15 April 1991 and accepted in revised form 31 
January 1992.  
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Methods 
 We made a record of the chest X-ray appearances, 
bacteriological status, tuberculin status and response to 
treatment of all patients with mycobacterial disease known to 
be HIV-positive and also patients who were known to be 
IVDU. Tuberculin skin hypersensitivity is routinely tested 
using PPD-RT23 (Staten Serum Institute, Copenhagen) and 
the Mantoux technique. 
 All chest X-rays are read and classified in accordance 
with the recommendations of the National Tuberculous 
Association of the U.S.A. (15). 
Results 
 On 1 January 1990 there were 910 known cases of HIV 
infection in the Republic of Ireland. One-hundred and twenty-
four cases of AIDS had been diagnosed of whom 58 had died. 
 In the study period we treated 1000 cases of tuberculosis 
and 11 cases of MOTT. Eighteen patients were HIV-positive. 
We are aware of two further HIV-positive patients (both 
haemophiliacs) who were diagnosed as having TB but who 
were not admitted under our care and are not included in this 
study. 
 Of the 18 patients (15 males, three female) who were 
HIV-positive; 12 were IVDUs of whom one was also a 
prostitute and one a bisexual; six HIV-positive patients were 
homosexual/bisexual. Six patients with TB (three male, three 
female) were known IVDUs and HIV-negative. 
 Six of the HIV-positive patients had other features of 
CDC stage IV disease at the lime tuberculosis was diagnosed 
— PCP pneumonia and oral candidiasis (one); PCP 
pneumonia (one); oropharyngeal can-didiasis (three); recurrent 
bacterial pneumonia and anaemia (one). Three patients were 
receiving Zidovudine (AZT) at the time mycobacterial disease 
was diagnosed. 
 Seven HIV-positive patients and three HIV-negative 
patients were known to have received previous BCG 
vaccination. The chest X-ray appearances, tuberculin skin test 
results and organisms isolated are shown in Table 1. All strains 
of Mycobacterium tuberculosis isolated were fully sensitive. 
Extrapulmonary tuberculosis (genito-urinary TB, TB 
meningitis, cervival and axillary gland TB, ischiorectal 
abscess) occurred in ten HIV-positive patients and three HIV-
negative patients. 
 Patients with TB were treated with standard therapy 
(13,14) unless contraindicated by associated hepatic disease or 
drug intolerance. The patients with MOTT were treated with 
other drug combinations (Cycloserine 500 mg b.d., 














Table 1 Radiological appearances, extent of disease, Mantoux 
status and Mycobacteria isolated in all patients 
No. patients  
HIV-
positive 
(n = 18) 
HIV-negative/IVDU
(n = 6) 
Chest X-ray 
Atypical 12 0 
Miliary 1 2 
Pleural effusion 1 0 
Minimal 0 1 
Moderate 1 1 
Advanced 2 2 
Not available 1 0 
Extrapulmonary TB 10 3 
Mantoux result 
Positive 1TU 5 4 
Positive 10TU 5 2 
Positive 100TU 2  
Negative 100TU 2  
Incomplete 4  
Mycobacterium 
tuberculosis 12 6 
M.O.T.T. 3 0 
No mycobacteria   
cultured 3 0 
Rifabutin 300-600 mg daily, Clarithramycin 500mg b.d.). 
 Seven patients, (six HIV-positive and one HIV-negative 
IVDU) were lost to follow-up before completion of treatment. 
Four of these patients were positive on direct staining and 
culture for tuberculosis at the time they were lost to follow-up. 
Three HIV-positive patients died before completing treatment 
(one Mycobacterium kansasii, two non-mycobacterial causes). 
Two HIV patients, both with MOTT, have had no response to 
treatment. The remaining 12 patients (seven HIV-positive. live 
HIV-negative) have responded to treatment and completed 
their anti-tuberculous drug regimen. 
 Table 2 shows the time for patients to become 
consistently direct smear (S) and culture (C) negative for all 
patients. This is not significantly different from the conversion 
rates we have seen in trial protocol with standard anti-
tuberculous treatment (13). The six patients who were smear 
negative were unproductive of sputum. Three of these patients 
were positive on culture of broncho-alveolar lavage; one was 
positive on urine culture; one had a strongly positive ITM 
Mantoux with chest X-ray appearances consistent with 
tuberculosis; and one had therapy initiated in the U.K. where 
he had been positive on culture of pleural fluid for fully 











Table 2 Time for sputum to become bacteriologically negative 
for M. tuberculosis 
No. patients 
HIV-positive 
(n = 12) 
HIV-negative/ 
IVDU 
(n = 6) Duration of treatment 
(weeks) S- C- S- C- 
1 5 3 1 0 
4 7 8 4 4 
8 7 8 4 4 
12 7 8 5 5 
26 9 9   
Four patients (three of whom were HIV-positive) were 
positive on direct staining and culture at the time they were 
lost to follow up. S-, Direct smear negative; C-, culture 
negative. 
relapsed with fully sensitive Mycobacterium tuberculosis 3 
months after completion of chemotherapy. He admitted 
ongoing drug abuse and poor compliance after 10-12 weeks of 
therapy. He has since become consistently negative on direct 
staining and on culture with supervised chemotherapy. 
 Statistical analysis using the X2 technique comparing our 
experience between 1980 and 1985 (16) with 1986–1990 
showed that there were statistically significantly more IVDUs 
treated for tuberculosis in the latter period (P = < 0.00001; 
d.f. 1, X2= 20.38). Analysis of patients admitted to Peamount 
in the latter period showed no significant geographical shift in 
referral pattern and we continued to treat 28-32% of all 
reported cases of tuberculosis in the Republic of Ireland. 
Consultation with the drug addiction treatment centres in 
Dublin have shown that all known IVDUs with TB attending 
the centres were treated by us. 
Discussion 
 Twelve of the 24 patients described in this study were 
intravenous drug abusers. This shows a statistically highly 
significant increase in tuberculosis in IVDUs in Dublin since 
our previous study (16). Six of these patients were HIV-
positive and these results suggest that the AIDS epidemic is 
contributing to an increased incidence of TB in the IVDU 
population in Dublin. 
 The numbers remain small but form a significant 
percentage of the total patients with AIDS and a significant 















managing patients, particularly those with manifestations of 
AIDS. Tuberculosis is also important in that it was the first 
indicator of Stage IV disease in 11 of 18 patients who were 
HIV-positive. 
 While advice with respect to safe sex and needle 
exchange programmes may help reduce the transmission of HI 
V. it will have no effect on the transmission of tuberculosis. 
One feature of the problem is that four patients (all IVDU) 
were lost to follow-up at a time when they were still positive 
on direct staining and culture. The organism will remain 
pathogenic (17) and because compliance in these patients is 
likely to be poor, they must be regarded as a serious ongoing 
source of transmission of tuberculosis. 
 While it has been suggested that patients with 
tuberculosis should perhaps be considered for HIV screening, 
experience in the Republic of Ireland to date suggests that this 
would not be appropriate or necessary at this time. It has been 
suggested (11,18,19) that patients who are infected with HIV 
and have a positive skin test should be offered 
chemoprophylaxis or definitive treatment for tuberculosis to 
prevent them developing active disease. This may also help 
prevent the associated immunosuppression seen with 
tuberculosis (20) and perhaps prevent acceleration of 
progression to AIDS (2). 
 A difficulty in interpreting tuberculin skin test status in 
the Republic of Ireland is that the majority of young adults 
will have had BCG vaccination either as infants or at 12-14 
years of age. In their study Selwyn et al. (6) could regard the 
Mantoux test as indicative of previous infection as routine 
BCG vaccination is not the practice in the United States. A 
further difficulty is deciding on the significance of skin anergy 
(negative 10 TU Mantoux) in patients infected with HIV as the 
negative test could indicate deteriorating T-cell function and 
progression towards AIDS. HIV-positive patients with chest 
symptoms or pyrexia of unknown origin and positive 
tuberculin skin tests must be assessed for active tuberculosis. 
 The duration of chemotherapy for patients with HIV 
AIDS for tuberculosis is not clear. These patients seem to 
respond equally well to therapy but there are problems with 
IVDUs particularly with compliance and other disease 
processes, particularly hepatitis B. We have had a policy of 
isoniazid prophylaxis indefinitely following completion of 
therapy because of possible reactivation and/or reinfection. 
Special procedures to ensure compliance with chemotherapy 
by IVDUs who have active tuberculosis are necessary and 
ideally they should receive fully supervised therapy. 
 Our study does not suggest that BCG gave useful 















subjects but it was not designed to detect protection against 
tuberculosis from BCG. We have previously reported the 
protective effects of BCG on younger subjects in the Republic 
of Ireland (21,22) but there is no reason to believe that this 
finding may be extrapolated to HIV-positive individuals. 
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